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Metastasis remains the most formidable obstacle incancer therapy. While there
is reasonable evidence to suggest the existence of a natural cellular surveillance
against the development of certain neoplasia (1), as well as the metastatic spread
of tumor cells via circulation (2), such a surveillance often fails to contain the
growth of most primary tumors or their metastatic dissemination. We have
recently shown (3) in a number of murine tumor models, that the host NK cell
activity declines rapidly during the development of transplanted or spontaneous
tumors. This decline results from neither the disappearance of NK lineage cells
(3) nor their maturation arrest (4), but from their rapid inactivation by the host-
derived NK suppressor cells appearing in the lymphoid organs, as well as at the
tumor site (4). They have been characterized as cells of the mono-
cyte/macrophage class with phagocytic ability and bearing surface Mac-1. Their
suppressor function is mediated by PG, and is abrogated in the presence of
indomethacin, an inhibitor of PG synthesis (4). We have further noted that
tumor-derived macrophages, or chemically pure PGE2 can block a variety of
lymphocyte responses in vitro: functional activation of NK cells, lectin (Con A)-
induced lymphocyte proliferation and generation of killer cells, alloreactive
proliferation ofTcells and their subsequent differentiation into CTL, as well as
the generation of lymphokine (rIL-2)-activated killer (LAK)' cells, the macro-
phage-mediated suppression being preventable in the presence of indomethacin
(Lala, P. K., and R. S. Parhar, unpublished observations). These results suggest
that the production of PG, particularly ofthe E series (PGE), may have pansup-
pressor effects against the activation of various classes of effector cells with
tumoricidal potential in vivo in the tumor-bearing host. While the source ofPGE
has been identified as host macrophages in numerous tumor models in our study
(4), certain tumors may also be capable ofproducing PGE (5). Furthermore, we
have identified two important mechanisms of PGE2-mediated blockade of T cell
activation in the presence ofalloantigens or a polyclonal mitogen Con A: a down
regulation of IL-2-R development on the stimulated lymphocytes, and an inhi-
bition of production of IL-2 by these cells; we saw no effect on the interaction
between IL-2-R and IL-2, nor on the lytic function of CTL once generated (6).
This work was supported by the National Cancer Institute of Canada and the Medical Research
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'Abbreviations used in this paper:
￿
AGM1, asialo-GM-1 ; CCDF, cytotoxic cell differentiation factor;
LAK, lymphokine-activated killer cell ; LICC, lymphokine-induced cytotoxic cells.
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A down regulation of transferrin receptor development on T cells has also been
documented (7). While the precise mechanism of PGE2 action on NK lineage
cells remains to be fully understood, a suppression of their activation (4) as well
as their killer function (8, 9) has been documented.
We have recently examined the in vivo relevance of the PG-mediated suppres-
sion of natural host defence against cancer cells to their metastatic spread from
the primary site (9). Using three C3H mammary carcinoma lines derived from a
single spontaneous tumor, but varying in their lung metastasizing ability, we
have observed that chronic indomethacin therapy shortly after a subcutaneous
tumor transplantation produces the following effects: (a) a reduction in the
growth of the primary tumor, (b) a prevention of lung metastasis, (c) a restoration
of host NK activity, and (d) an abrogation of NK suppressor function of tumor-
infiltrating macrophages (9) . These results suggest that the PG-mediated NK
suppression promotes tumor metastasis, which can be contained by indomethacin
therapy . However, we find that lung metastasis from the primary tumors, once
well established and advanced, can not be completely cured with indomethacin
therapy when the therapy is provided at later intervals (Parhar, R. S., J. Nelson,
and P. K. Lala, unpublished observations). Encouraged by the recent success of
a combination therapy with IL-2 and LAK cells of established tumors and their
metastases in mice (10-18) and man (18, 19), the present study was designed to
test whether a combination therapy with indomethacin and IL-2 is superior to
indomethacin alone or IL-2 alone in ameliorating established experimental
metastasis of B 16F 10 melanoma cells. The rationale of this study was based on
the contention that a relief of the endogenous suppression with indomethacin
would allow a generation of sufficient levels of IL-2-R on the various effector
lineage lymphocytes, which then can be stimulated further by the exogenous IL-
2 provided over and above the endogenous IL-2 levels achieved by such therapy.
Furthermore, we examined the characteristics of the splenic effector cells gen-
erated by such therapeutic measures in vivo, as revealed by their surface phe-
notype and cytocidal spectrum .
Materials and Methods
Mice.
￿
Youngadult (8-10 wk old) C57BL/6 (henceforth called B6) mice (The Jackson
Laboratory, Bar Harbor, ME) were used as hosts for the production of experimental
metastasis.
Tumor.
￿
B16F 10, a melanoma line with high lung metastasizing ability, produced
initially by 1. J. Fidler (20, 21), was obtained through the courtesy of A . Chambers of the
Department of Radiation Oncology, The University of Western Ontario. This line, in our
hands, does not produce any significant level of PGE2 in vitro. Cells grown in tissue
culture were injected intravenously at a high inoculum dose of 106 cells per mouse to
produce experimental lung metastasis. Mice killed on day 5 all showed large numbers of
well-established foci of microscopic metastases (micrometastases) in both lungs. Mice killed
on day 10 all exhibited high numbers of visible (macro) metastases . Hosts usually died
during week 4 after injection. Those killed on day 21 or autopsied at death showed
confluent lung metastases of various sizes, and occasional melanotic foci in the liver. The
experimental protocol was designed on the basis of this background information.
Experimental Protocol for Therapy.
￿
A total of 35 animals were injected intravenously
via the tail vein with 106 melanoma cells. They were randomly assigned to seven groups
of five animals per group. Five groups of experimental animals were subjected to the
following therapeutic protocols: (Group 1) Indomethacin (Sigma Chemical Co., St. Louis,
MO), at a concentration 14 ug/ml in drinking water, provided throughout the experi-16
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mental period from day 0 to day 21 . Indomethacin was initially dissolved in absolute
ethanol and then diluted in drinking water, resulting in a concentration of 0.2% ethanol,
as reported earlier (9). Bottles were changed twice a week with freshly prepared materials .
(Group 2) Indomethacin at a similar concentration provided from day 5 to day 21 . (Group
3) Human rIL-2 (22, 23) (produced in Escherichia coli, lots 9A and LP9C, kindly supplied
by the Cetus Corp., Emeryville, CA), 25,000 U per inoculum, injected intraperitoneally
every 8 h for 5 d on days 10-14. (Group 4) Indomethacin, as given to group 1, plus rIL-
2 as given to group 3. (Group 5) Indomethacin as given to group 2 plus rIL-2 as given to
group 3 . Two groups of control animals were used: the first group received vehicle alone
used for dissolving indomethacin, i . e., 0.2% ethanol in drinking water throughout the
experimental period (day 0-21); and the second group received the same drinking vehicle
as above (day 0-21), plus intraperitoneal injections of the excipient control (solvent buffer
for IL-2) every 8 h for 5 d (days 10-14).
Experiments were repeated for a second time to include group 1 as above in the control
series, and groups 2 and 5 in the experimental series, using six mice per group. Since
these essentially reproduced the results of the first series, the detailed results of the second
series will not be presented.
Killing ofAnimals.
￿
All animals (both experimental and control groups) were killed on
day 21, followed by a thorough visual examination of all internal organs for visible
melanotic nodules, identifiable on the basis of the black melanin pigment. Lungs were
removed and fixed in Bouin's Fixative for melanoma colony counts (24) and subsequent
histological preparation. With this fixation procedure, black melanotic nodules stood out
prominently on the light yellow background. Freshly isolated spleens were used to make
single cell suspensions, free from red cellsand debris (3), for use as effector cells in killer-
cell assays against numerous tumor targets. For this purpose, cells were pooled from the
animals in each group.
Killer-Cell Assay.
￿
A 4-h "Cr-release assay, as described earlier (3), was used to measure
the percent specific cytotoxicity of spleen cells at various E/T ratios (12 .5:1-100:1). The
cytocidal spectrum was assessed by using the following tumor targets, all obtained from
exponential phase growth in tissue culture and exhibiting >98% viability: YAC-1 lym-
phoma (a highly NK-sensitive line); B16F10 melanoma (a moderately NK-sensitive line in
our hands), and thymic lymphoma 9705 (an NK-resistant line, kindly provided by Dr. F.
P. H. Chan of the Department of Anatomy, The University of Western Ontario).
Phenotyping ofKiller Cells.
￿
Killer cells were phenotyped for the presence of the surface
markers Thy-1, Lyt-2, and asialo-GM-1 (AGM1) by using a complement-mediated cyto-
toxicity assay in the presence of appropriate antibodies. Monospecific anti-Thy-1 .2 anti-
body (E Thy-1 .2 of the National Institutes of Health [Bethesda, MD] catalogue, courtesy
of Dr. ,J. G . Ray, NIH) and anti-Lyt-2 mAb (Becton Dickinson & Co., Sunnyvale, CA)
were used at 1 :20 dilution. Rabbit anti-AGM 1 (Wako Chemicals, Dallas, TX) was used at
1 :200 dilution . Rabbit complement (low tox, Cedarlane Laboratories, Hornby, Canada)
was used at 1 :20 dilution. These dilutions were based on control studies. Untreated spleen
cells, or spleen cellstreated with complementalone (controls), or with appropriate antibody
(at 4°C for 45 min, followed by three washes), followed by complement (at 37°C for 45
min, followed by three washes) were used as effector populations. The E/T ratio was
computed on the basis of the effector cell number before antibody or complement
treatment so that the results could not be biased by an enrichment of a particular subset
in the surviving effector population (25). All the treatment and the washes were carried
out in the same tube to avoid any cell loss by transfer.
Statistical Evaluation.
￿
The significance ofdifferences in the number of lung metastases
between any two groups was determined by the Wilcoxon rank sum tests, using two-sided
p values (26).
Results
Effects of Various Therapeutic Protocol on Experimental Lung Metastasis.
￿
Visible
melanoma nodules detectable on day 21 after an intravenous inoculation of 106
melanoma cells reached a confluence in many of the control animals, thePARHAR AND LALA
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TABLE I
Effects ofVarious Therapeutic Measures on Lung Colony Number
* Data in the twocontrol groups were very similarandthus were pooled.
The maximum number of countable nodules shorto£ confluence was ^"600.
Only oneanimal showed five nodules.
' Only oneanimal showed nine nodules.
§ Data in parentheses represent results from thesecond series of experiments.
maximum scorable number in a pair of lungs being ^-600. Both control groups
provided very similar data and are thus pooled in Table I. Two of five animals
in each control group also showed a small number of nodules on the surface of
the liver, but on no other organs such as kidneys, spleen, intestine, mesentery,
or reproductive organs. The two protocols ofindomethacin administration alone
(starting on day 0 or day 5) and the protocol of IL-2 therapy alone led to a
substantial (all significant at p «0.01) and very similar (63-68% median) reduc-
tion in the lung nodules as compared with the control animals. There was no
significant (p »0.1) difference between any two of these three experimental
groups. A combination therapy with indomethacin plus IL-2, irrespective ofthe
onset ofindomethacin therapy (i. e., day 0 or 5) led to a complete freedom from
visible melanotic foci on the lung surface in all animals, except one animal in
each group that showed a small number of residual nodules also heterogeneous
in size (Table I). The reduction ofmetastases with either protocol ofcombination
therapy was highly significant (p «0.01) compared with the control or either of
the indomethacin groups, or the group receiving IL-2 alone. There was no
significant difference (p »0.1) in the results provided by the two protocols of
combination therapy. None of the experimental animals exhibited any liver
nodules. Representative photographs of the lungs are presented in Fig. 1.
A repetition of some of these experiments (second series) closely reproduced
the results ofthe first series, as indicated by the data in parentheses in Table I.
A histological examination of the lungs that exhibited visible surface nodules
also showed the presence of tumor cell foci in sections. Sections of nodule-free
lungs of mice that had received a combination therapy were also free from
microscopic foci of tumor cells. However, whether these lungs were totally
devoid of tumor cells can only be answered on the basis ofserial sections, which
have not yet been performed. All experimental lungs exhibited visible levels of
mononuclear cell infiltration. The infiltration was higher with IL-2 therapy than
Number of macroscopic melanoma nodules in the two
Protocol
Range
lungs (day
Mean
21)
Median
Percent re-
duction
(median)
Control* 221-600+$ 418 473 0
(297-600+)§ (471) (473) (0)
Indomethacin alone (days 0-21) 97-192 163 176 63
Indomethacin alone (days 5-21) 157-201 175 173 64
(193-278) (224) (213) (55)
IL-2 alone 102-174 146 152 68
Indomethacin (days 0-21) + IL-2 0-5w 1 0 100
Indomethacin (days 5-21) + IL-2 0-9' 2 0 100
(0-17) (9.5) (9) (98)18
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FIGURE 1 .
￿
Representative photographs of the lungs from melanoma-inoculated mice . (A)
Control mouse receiving 0.2% ethanol in drinking water from day 0 and excipient buffer (for
dissolving IL-2) intraperitoneally on days 10-14 . (B) Mouse receiving indomethacin alone
from day 0 . (C) Mouse receiving indomethacin alone from day 5 . (D) Mouse receiving IL-2
alone on days 10-14 . (E) Mouse receivingindomethacin from day 0 plus IL-2 on days 10-14 .
(F) Mouse receiving indomethacin from day 5 plus IL-2 on days 10-14 .
with indomethacin therapy and was most marked with the combination therapy .
In the latter case, alveoli in some areas of the lungs were totally replaced by
young granulation tissue containing mononuclear cell exudate, possibly repre-
senting the sites of clearance of the original tumor foci . Representative histolog-
ical pictures are presented in Fig . 2 .
Cytocidal Spectrum and the Phenotype of Splenic Killer Cells Generated In Vivo .
Results are only presented for the first series of experiments, since the second
series closely reproduced the data as presented in the first series .
YAC-I Target .
￿
Figs . 3 and 4 present the results ofpercent specific cytotoxicityPARHAR AND LALA
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FIGURE 2 .
￿
Representative photomicrographs (x 160) ofHand E-stained sections ofparaffin-
embedded lungs of (A) mouse killed on day 5 after intravenous inoculation of 10 6 cells; (B)
control mouse receiving 0.2% ethanol in drinking water from day 0 and excipient buffer (for
dissolving IL-2) intraperitoneally on days 10-14 ; (C) mouse receiving IL-2 alone ; (D) mouse
receiving indomethacin from day 0 plus IL-2 on days 10-14 ; (E) mouse receivingindomethacin
from day 0 plus IL-2 on days 10-14; (F) mouse receiving indomethacin from day 5 plus IL-2
on days 10-14 . T, melanoma tumor nodules in A-D. Note variable degrees of interstitial
mononuclear cell infiltration in C-F, more marked inD than in C and most marked in E and
F.A large area ofyoung granulation tissue represented by mononuclear cell exudate (indicated
by M), replacing alveoli is shown in F. Such areas are encountered in both groups E and F,
although not shown in E. They possibly represent the replacement sites of original melanoma
nodules .
of normal spleen, spleen of control tumor-inoculated mice, or experimental
tumor inoculated mice subjected to different therapeutic protocols . As expected,
YAC-1 target was sensitive to lysis by normal B6 splenic effector cells that20
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FIGURE 3.
￿
Anti YAC-1 cytotoxicity of splenic effector cells (subjected to various treatments)
from normal healthy mice and tumor-inoculated mice treated with vehicle alone or indometh-
acin. Control (vehicle alone) group received 0.2% ethanol in drinking water from day 0.
Control animals receiving the same treatment plus excipient buffer intraperitoneally (days 10-
14) provided very similar results and are not presented. Effector cells were pooled from five
mice in each group. Data represent means from triplicate wells with <5% variation. Indo,
indornethacin.
expressed surface AGMI but not Thy-1 or Lyt-2. Killer activity was reduced to
near background levels in the spleen of control tumor inoculated groups.
Treatment with indomethacin alone beginning on day 0 caused a substantial
restoration of the killer activity measured on day 21, again AGM1+, Thy-1 - and
Lyt-2- cells. Similar but somewhat less marked effects were produced by indo-
methacin therapy beginningon day 5 (Fig. 3). IL-2 therapy alone (Fig. 4) restored
the killer function to above normal levels, and the effector cells were AGM1 +,
Thy-1-, and Lyt-2-. Combination therapy with IL-2 plus indomethacin startingKing of YAC t targets by
* splenocytes
o + C'
￿
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￿
+C'
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￿
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EFFECTOR/TARGET RATIO
FIGURE 4.
￿
Anti YAC-1 cytotoxicity of splenocytes (subjected to various treatments) from
tumor-inoculated animals treated with IL-2 alone or indomethacin plus IL-2. Effector cells
were pooled from five mice in each group. Data represent means from triplicate wells with
<5% variation. Indo, indomethacin .
either on day 0 or on day 5 stimulated the killer activity further and the killer
cells were ofthe identical phenotype (Fig. 4).
B16F10 Target.
￿
B16F10 was found to be moderately sensitive to lysis by
normal splenic effector cells, which also proved to be of the classical NK
phenotype, i. e., AGMI+, Thy-1-, and Lyt-2` (Fig. 5). Cytotoxic responses of
this target to spleen cells from control tumor-inoculated mice or tumor-inocu-
lated mice subjected to various therapeutic protocols were nearly identical to
that of YAC-I target, except for the fact that with indomethacin alone starting
on day 0 or day 5, there was a complete restoration of killer function (Figs. 5
and 6). The killer cell phenotype, on all occasions, was again AGM1+, Thy 1-,
Lyt 2-.
Thymic Lymphoma 9705 Target. As shown by the poor cytolytic ability of
normal splenic effector cells (Fig. 7), this tumor line is relatively NK resistant.
Tumorbearing caused a further reduction ofthe splenic effector function, which
was restored to control levels by indomethacin therapy starting on day 0 or day
5. IL-2 alone or IL-2 combined with indomethacin in either protocol caused an
appreciable stimulation of killer activity above normal levels, the highest stimu-
lation being provided with the combination therapy of IL-2 plus indomethacin
beginning on day 0. In all cases, a nearly complete loss ofeffector function was
only achieved with anti AGM1 + C', indicating that the effector cells were again
AGM1+, Thy-I-, and Lyt-2-.22
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FIGURE 5.
￿
Anti-BI6FI0 cytotoxicity of splenocytes (subjected to various treatments) from
normal healthy mice and tumor-inoculated mice treated with vehicle alone or indomethacin.
Control (vehicle alone) group is the same as in Fig. 3. Those receiving, in addition, the
excipientbuffer intraperitoneally, provided nearly identical data (not presented). Effector cells
were pooled from five mice in each group. Data represent means from triplicate wells with
<5% variation. Indo, indomethacin.
Chronic administration of indomethacin by the oral route (14 Jug/ml of
drinking water) or a 5-d regimen ofintraperitoneal administration of 25,000 U
IL-2 every 8 h led to a similar and substantial, but incomplete, containment of
experimental lung metastasis produced by an intravenous injection of 10'
B16F10 melanoma cells in B6 mice. Lack ofany appreciable difference between
the effects of the indomethacin regimen initiated on day 0 and day 5 can be
explained by our earlier observations that tumor transplantation in mice causesr
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FIGURE 6. Anti-1316F10 cytotoxicity of splenocytes (subjected to various treatments) from
tumorinoculated mice treated with IL-2 aloneor indomethacin plus IL-2. Effector cellswere
pooled from five mice in each group. Data represent means from triplicate wells with <5%
variation. Indo, indomethacin. Killing of B16F10 melanoma targets by: ", splenocytes; O, +
C' ; A, + anti-Thy-1 + C'; A, + anti-asialo GM-1 + C' ; O, + anti-Lyt-2 + C'.
a transient and abortive stimulation of host NK activity, followed by a lasting
suppression of this activity beginning on days 6-7 (3). Present results of indo-
methacin therapy alone are in agreement with reports from our own (9) as well
as other laboratories (27-30) of the containing effects of this agent on tumor
growth, and more importantly on the natural metastasis from the primary site.
Similarly, the present results of IL-2 therapy alone, in spite of some differences
in the protocol, are in essential agreement with those reported by Rosenberg's
group in several murine models of metastasis, including other lines of B16
melanoma (10, 12-16, 18, 31). The inadequacy of indomethacin alone or IL-2
alone to affect a complete regression ofestablished metastasis during the exper-
imental period is explicable on the following grounds: (a) a relief ofthe endog-
enous PG-mediated suppression may permit a regeneration ofIL-2 receptors on
the effector lymphocytes as well as an improved synthesis of endogenous IL-2
(6), but the latter may still be inadequate for a maximal and sustained activation
of the effector cells; (6) exogenous IL-2 alone may fail to cause an optimal
stimulation, because of an inadequate generation of IL-2 receptors (6) on the
effector lineage cells, if the endogenous suppression is not relieved. Such PG
mediated suppression may, in addition, inhibit the production of other lympho-
kines such as IL-1 (32, 33) and cytotoxic cell differentiation factor (CCDF) (34-
36), which are believed to be required for the lymphocyte activa-
tion/differentiation pathway. These possibilities are supported by our findings
that chronic indomethacin treatment combined with a single round of IL-2
therapy led to a complete or nearly complete amelioration ofexperimental lung
metastasis generated by a very high inoculum of B16F10 melanoma cells in a
highly reproducible manner. The beneficial effects of this combination therapy
seem to be comparable to the effects of combined IL-2 and LAK cell therapy of
metastasis in the murine system (10-18). Furthermore, we have recently notedY
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FIGURE 7.
￿
Cytotoxicity of splenocytes (subjected to various treatments) from normal healthy
mice, and tumor-inoculated control and experimental mice (subjected to various therapeutic
protocols) against the thymic lymphoma 9750. Control (vehicle alone) groupis the same as in
Fig. 3. Those receiving, in addition, the excipient buffer intraperitoneally, provided very
similar results (not presented). Effector cells were pooled from five mice in each group. Data
represent means from triplicate wells with <5% variation. Indo, indomethacin. Killing of
thymomatargets by: ", splenocytes; O, + C' ; A, + anti-Thy-I + C' ; A, anti-asialo GM I + C';
0, anti-Lyt-2 + C'.
(Parhar, R. S., J. Nelson, and P. K. Lala, unpublished observations) that a
combination of indomethacin and IL-2 can also cause a marked regression of
spontaneous lung metastasis developing from a primary murine adenocarcinoma.
The effector cells generated in the host spleen by indomethacin alone, IL-2
alone, or a combination of indomethacin plus IL-2 in vivo, all expressed AGM I .
This by itself cannot be considered as an exclusive NK cell marker, since AGMI
expression has also been reported (37) for cytotoxic T cells. However, an absence
of Thy-1 or Lyt-2 on these cells indicates an NK-like phenotype. A superior
functional activation of these effector cells was always achieved with the combi-
nation therapy, irrespective of the tumor target tested. With indomethacin alone,
the cytolytic activity was essentially confined to the NK-sensitive targets YAGI
and B16F10 . Administration of IL-2 generated a broader spectrum of killer
function extending also to the NK-resistant target thymic lymphoma 9705, thePARHAR AND LALA
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killer activity being more marked with the combination therapy. Although this
would suggest the generation of LAK-like cells in vivo, typical LAK cells
generatedin in vitro exhibitadifferent phenotype. Theyare Thy-1+andAGMl-
and Lyt-2± (17, 18, 35; our unpublished observations). Another closely related
effector cell class with a broad cytocidal spectrum generated in vitro from NK-
like precursor cells requires the presence of IL-2 and a newly described lympho-
kine, CCDF, produced by macrophages in the presence of indomethacin (34-
36). This cell class has been named lymphokine-induced cytotoxic cells (LICC),
which are Thy-1+, Lyt-2-, and AGM1- (35). With the present combination
therapy, one would expect that LICC and LAK cells should have been generated
in vivo. Several possible explanations maybeoffered for the observed phenotypic
discrepancy: (a) the effector cell phenotype may depend on its activation and
differentiation status (36, 38) and may have been influenced in our case by a
termination ofthe IL-2 therapy one week before mice were killed. In indometh-
acin-treated animals killed shortly after IL-2 therapy, splenic effector cells are
found to be AGM1+ and Thy-I' (Parhar, R. S., and P. K. Lala, unpublished
observations); (b) an expression of Lyt-2 on the anti-tumor effector cells gener-
ated by IL-2 therapy in vivo may depend on the immunogenicity of the tumor
concerned. The effector cells are Lyt-2+ when tumors have detectable immuno-
genicity, but are Lyt-2- in the case of nonimmunogenic tumors (39), suggesting
that IL-2 therapy may recruit both NK and Tlineage cells; and (c) in the present
study, the effector cells were sampled from the spleen and not from the tumor
site i. e., the lungs, where a different subset may accumulate preferentially. Our
preliminary (unpublished) studies reveal that AGM1'}, Thy-1+ effector cells with
high anti-B16F10 killer activity can be recovered from the lungs of the animals
subjectedto the combination therapy. The cytocidal spectrumandthe phenotype
of the various mononuclear cells infiltrating in situ, as well as the long term
survival ofmice placed under combination therapy, are currently under investi-
gation .
Summary
Our earlier work revealed that PGE-mediated inactivation of NK cells in
tumor-bearing mice by host macrophages promoted spontaneous lung metastasis
that could be prevented or ameliorated by chronic indomethacin therapy. Since
PGE was found to suppress the in vitro development and/or activation of a
family of tumoricidal lymphocytes such as CTL, NK, and LAK cells by one or
both of two mechanisms, that is to say, a down regulation of IL-2-R and an
inhibition of IL-2 production, the present study tested whether a combined
therapy with indomethacin and IL-2 was more effective than one with indometh-
acin or IL-2 alone in ameliorating established experimental lung metastasis. B6
mice injected intravenously with 106 highly metastatic B16F10 melanoma cells
showed profuse micrometastases in the lungs by day 5, and macrometastases by
day 10 which were confluent on day 21. Chronic indomethacin therapy by the
oral route (14 wg/ml in drinking water) starting on day 0 or day 5, or a single
round of IL-2 therapy (25,000 U rIL-2, every 8 h for 5 d on days 10-14)
reduced the number of metastatic nodules by two-thirds (from a median of 473
in control mice receiving vehicles alone) by day 21. A single round of IL-2 as
above, combined with either protocol of indomethacin therapy, completely or26
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nearly completely irradicated the lung metastases, corroborated by a histological
examination . An evaluation of splenic killer cell activity measured with a 4-h
"Cr-release assay against NK-sensitive YAC-1 lymphoma and BI 6F10 melanoma
or NK-resistant thymic lymphoma 9705 targets revealed negligible activity in
control tumor-bearing mice, and a good restoration of activity against NK-
sensitive targets with either protocols of indomethacin therapy. IL-2 alone or a
combination of IL-2 and indomethacin given by either protocol generated strong
killer activity against all these targets, most marked with the combination therapy .
Splenic killer cell phenotype in normal as well as all treated animals was ASGM I',
Thy-1 -, and Lyt-2-. The combination therapy resulted in the strongest mono-
nuclear cell infiltration in the lungs, with areas of young granulation tissue
suggestive of repair sites of original metastases.
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